Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Aurinia Pharmaceuticals's operating assets for the quarter that ended in Mar. 2026 was $345.2 Mil. Aurinia Pharmaceuticals's operating liabilities for the quarter that ended in Mar. 2026 was $87.7 Mil. Aurinia Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was $751.6 Mil. Therefore, Aurinia Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.34.
Aurinia Pharmaceuticals Scaled Net Operating Assets Related Terms
Aurinia Pharmaceuticals Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Aurinia Pharmaceuticals's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurinia Pharmaceuticals Scaled Net Operating Assets Chart
AUPH vs KOD, ABCL, AGIO: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Aurinia Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurinia Pharmaceuticals Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Aurinia Pharmaceuticals's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.34 mean?
Aurinia Pharmaceuticals (AUPH) has a Scaled Net Operating Assets of 0.34 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Aurinia Pharmaceuticals and its competitors.
Is Aurinia Pharmaceuticals' Scaled Net Operating Assets too high?
Aurinia Pharmaceuticals' current Scaled Net Operating Assets is 0.34. Overall, Aurinia Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' Scaled Net Operating Assets compare to KOD and ABCL?
Aurinia Pharmaceuticals' Scaled Net Operating Assets of 0.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Aurinia Pharmaceuticals and its competitors. Aurinia Pharmaceuticals's current Scaled Net Operating Assets is 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (AUPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $13.97, compared to a current price of $16.97 — trading 21.4% above its estimated fair value. The current Scaled Net Operating Assets is 0.34. Aurinia Pharmaceuticals' overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Aurinia Pharmaceuticals (AUPH), the current Scaled Net Operating Assets is 0.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurinia Pharmaceuticals (AUPH) Overvalued in 2026?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued.
The current stock price of $16.97 is trading 21.4% above its estimated GF Value™ of $13.97.
GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for AUPH:
Scaled Net Operating Assets: 0.34
GF Value™: $13.97 vs. price of $16.97 (21.4% above fair value)
No single metric tells the full story. See the AUPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
82GF Score
Get the complete analysis for AUPH
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AUPH has been successfully added to your 
